We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-label Adjunctive Zonisamide for Bipolar Disorder

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00047567
First Posted: October 10, 2002
Last Update Posted: December 14, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Elan Pharmaceuticals
October 8, 2002
October 10, 2002
December 14, 2015
July 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00047567 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Open-label Adjunctive Zonisamide for Bipolar Disorder
Not Provided
To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Bipolar Disorders
Drug: zonisamide
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
20
July 2002
Not Provided
  • Bipolar I/II
  • Average intelligence
  • Taking at least one, but no more than two mood stabilizers
Sexes Eligible for Study: All
6 Years to 17 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00047567
ELN-345-509
Not Provided
Not Provided
Not Provided
Not Provided
Elan Pharmaceuticals
Not Provided
Not Provided
Elan Pharmaceuticals
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP